OYSTER POINT PHARMA, INC. (OYST) Social Stream

Featured Post From StockTwits About OYST

$OYST just listened to the conference call. As always, I’m pleased with how organized and aggressive management has been towards the launch. I know I’ve already been contacted by a sales rep at my ophthalmology clinic. Again, the current valuation on this company makes no sense. They have $150 million cash on hand, burn about 70-80 million a year, are about to get $17.5 million from China soon. they also just secured a $125 million credit line to fund the launch, so hopefully no more secondaries any time soon. Their market cap is in the $360 million range. So a likely to soon be approved novel dry eye medicine is only worth $200 million? Xiidra was bought for $3.5 billion.